IDEAYA Biosciences (IDYA) Free Cash Flow (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Free Cash Flow of -$76.1 million for Q1 2026, up 17.45% sequentially from -$92.2 million in Q4 2025, and down 24.82% YoY from -$101.3 million in Q1 2025.
IDEAYA Biosciences (IDYA) Free Cash Flow (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Free Cash Flow for 9 years, with the latest figure at -$76.1 million in Q1 2026.
- Quarterly Free Cash Flow fell 24.82% year-over-year to -$76.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$88.6 million (up 66.55% YoY) and the FY2025 annual result came in at -$73.5 million, up 70.5% from the prior year.
- Free Cash Flow advanced to -$76.1 million in Q1 2026 per IDYA's latest filing, from -$92.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $143.6 million in Q3 2025 and troughed at -$121.9 million in Q4 2024.
- A 5-year average of -$35.5 million and a median of -$33.3 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow tumbled 395.63% in 2024, then soared 397.79% in 2025.
- Over 5 years, Free Cash Flow stood at -$20.3 million in 2022, then declined by 21.05% to -$24.6 million in 2023, then sank by 395.63% to -$121.9 million in 2024, then advanced by 24.31% to -$92.2 million in 2025, then grew by 17.45% to -$76.1 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$76.1 million, -$92.2 million, and $143.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | -88.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -88.84 Mn |
| Jun 30, 2026 | -88.84 Mn |
| Mar 31, 2026 | -76.14 Mn |
| Mar 31, 2026 | -76.14 Mn |
| Dec 31, 2025 | -92.24 Mn |
| Dec 31, 2025 | -92.24 Mn |
| Sep 30, 2025 | 143.58 Mn |
| Sep 30, 2025 | 143.58 Mn |
| Jun 30, 2025 | -63.81 Mn |
| Jun 30, 2025 | -63.81 Mn |
| Mar 31, 2025 | -61.00 Mn |
| Mar 31, 2025 | -61.00 Mn |
| Dec 31, 2024 | -121.86 Mn |
| Dec 31, 2024 | -121.86 Mn |
| Sep 30, 2024 | -48.21 Mn |
| Sep 30, 2024 | -48.21 Mn |
| Jun 30, 2024 | -33.86 Mn |
| Jun 30, 2024 | -33.86 Mn |
| Mar 31, 2024 | -45.14 Mn |
| Mar 31, 2024 | -45.14 Mn |